Figure 3. Biomarker expression after neoadjuvant therapy.

In all neoadjuvant treated tissue a markedly higher αvβ6 expression was identified in vital tumor tissue (A) compared to surrounding fibrosis or necrosis (B) after neoadjuvant therapy. CEACAM5 biomarker expression showed increased heterogeneity after neoadjuvant therapy in the tumor (C), therefore clear distinction between vital tumor and fibrosis and necrosis is not possible (C and D) (Objective 10x).”